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A B S T R A C T
Lifestyle interventions and physical activity remain the cornerstone of obesity management, as pharmacological
therapies (orlistat) are associated with gastrointestinal (GI) side effects. Combining orlistat with fibers can re-
duce side effects, improving compliance. Therefore, a fiber that inhibits lipase without side effects could help
treat obesity.
The aims of the present work were to assess whether alginate enriched bread could inhibit fat digestion, and
assess the acceptability of alginate bread and its effect on GI wellbeing.
A double-blind, randomised, controlled cross-over pilot study (NCT03350958) assessed the impact of an
alginate bread meal on; lipid content in ileal effluent and circulating triacylglycerol levels. This was compared
against the same meal with non-enriched (control) bread.
GI wellbeing and acceptability of alginate bread was compared to control bread through daily wellbeing
questionnaires and food diaries (NCT03477981). Control bread followed by alginate bread were consumed for
two weeks respectively.
Consumption of alginate bread reduced circulating triacylglycerol compared to control (2% reduction in
AUC) and significantly increased lipid content in ileal effluent (3.8 g ± 1.6 after 210min).
There were no significant changes to GI wellbeing when comparing alginate bread to control bread. A sig-
nificant increase in the feeling of fullness occurred with alginate bread compared to baseline and the first week
of control bread consumption.
This study showed that sustained consumption of alginate enriched bread does not alter GI wellbeing and can
decrease lipolysis, increasing lipid leaving the small intestine.
Further studies are required to demonstrate that reduced fat digestion through the action of alginate can
reduce fat mass or body weight.
1. Introduction
Obesity is defined as an excess of body fat, which results from an
imbalance between energy intake and energy expenditure (Trenell,
2015). The incidence of obesity is reaching epidemic proportions
worldwide (Galani & Schneider, 2007) and the condition is associated
with an increased risk of morbidity and mortality (Fontaine, Redden,
Wang, Westfall, & Allison, 2003). Currently there are limited approved
pharmacological therapies for managing obesity, and those that are
available are associated with negative gastrointestinal side effects, such
as; oily spotting on underwear, flatulence, urgent bowel movements,
fatty or oily stools, increased number of bowel movements, inability to
control bowel movements, gas with discharge, and loose stools
(Daneschvar, Aronson, & Smetana, 2016; Kang & Park, 2012). Although
there are a number of promising agents currently being assessed
(Hardy, Anstee, & Day, 2015) such as gut microbiome transplantations
(Jayasinghe, Chiavaroli, Holland, Cutfield, & O'Sullivan, 2016) and
Korean Mistletoe extract (Jung et al., 2013), lifestyle interventions
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T
incorporating weight loss and physical activity/exercise remain the
cornerstone of obesity management (Galani & Schneider, 2007; Thoma,
Day, & Trenell, 2012). However, clinical implementation and ad-
herence is difficult (Ayyad & Andersen, 2000).
An alternative approach to reducing the amount of energy con-
sumed is to reduce the absorption of macronutrients once consumed.
Fat is the most energy-dense macronutrient, and can account for up to
40% of the energy consumed in a Western diet (Mu & Høy, 2004).
Therefore, if the absorption of fat could be reduced once ingested, this
would be a valid target as a treatment for obesity (Drent & Vanderveen,
1993; Hadvary, Lengsfeld, & Wolfer, 1988). Pancreatic lipase is re-
sponsible for between 70 and 80% of fat digestion (Borel et al., 1994;
Carey, Small, & Bliss, 1983), therefore an attenuation of this would
reduce the digestion of fat, meaning fat passes through the upper gas-
trointestinal (GI) tract undigested (Carey et al., 1983; Mu & Høy, 2004).
Previous research has shown that tetrahydrolipstatin (orlistat) is able to
inhibit pancreatic lipase by covalently binding to its active site
(Hadvary et al., 1988; Hadvary, Sidler, Meister, Vetter, & Wolfer,
1991), and the drug has been shown to be effective in weight loss
studies (Hollander et al., 1998). However, due to the side effects ex-
perienced by patients, compliance with orlistat treatment has been re-
ported to be as low as 47%, even with the intervention of pharmacists
(Malone & Alger-Mayer, 2003; Sjostrom et al., 1998). Previous studies
have combined the administration of orlistat with dietary fibers such as
psyllium husk, to successfully reduce the GI side effects associated with
the drug (Cavaliere, Floriano, & Medeiros-Neto, 2001). Therefore a
dietary fiber that is able to inhibit pancreatic lipase without the side
effects of orlistat may be an effective and viable tool to combat obesity.
We have previously shown that alginate, a dietary fiber extract of
brown seaweed, is effective at reducing pancreatic lipase activity in
vitro (Houghton et al., 2015; Wilcox, Brownlee, Richardson, Dettmar, &
Pearson, 2014). We have also shown that alginate can be incorporated
into food products, and is released under simulated upper GI tract
conditions in vitro, where pancreatic lipase is active (Houghton et al.,
2014). The primary aim of this study was to assess whether bread with
the addition of alginate was able to inhibit fat digestion in ileostomy
patients. The secondary aim was to assess the acceptability and po-
tential of GI side effects of longer term consumption of alginate bread
on GI wellbeing in healthy volunteers.
2. Materials and methods
2.1. Materials
Chloroform, methanol and sodium chloride were purchased from
Sigma-Aldrich (Poole, UK) Total plasma triglycerides assay kits were
purchased from Amsbio (Abingdon, UK). Alginate MANUCOL DM was a
gift from FMC BioPolymer (Drammen, Norway). The standard white
bread and alginate bread were produced by Greggs Plc (Newcastle upon
Tyne, UK), with the alginate bread at 4% alginate (w/w) of wet dough.
Manucol DM was used because, when compared to a range of alginate it
made the best bread. The rate of alginate inclusion in bread was to
create a high fibre bread without seriously affecting the quality of the
bread, as determined by Greggs Plc. Manucol DM had a viscosity of
150–300mPa s (cp) for a 1% solution in deionised water, based on this
viscosity measurement an estimated average molecular weight was
250,000. The nutritional profile per 100 g for control bread was; energy
(kcal) 247, protein 10.2 g, carbohydrates 46.2 g, fat 1.7 g, fiber 3 g,
sodium 0.4 g, and water 36.8 g. The nutritional profile per 100 g for
alginate bread was; energy (kcal) 304.5, protein 7.6 g, carbohydrates
41.4 g, fat 13.3 g, fiber 2.8 g, Alginate 4 g, sodium 1.4 g, and water
29.9 g. Based on 15% loss in mass from baking the alginate con-
centration would have increased to 4.7%. The bakers added the addi-
tional fat to ensure that the alginate was evenly distributed within the
dough.
2.2. Methods
2.2.1. Acceptability study
The assessment of two week consumption of alginate bread was
performed with 54 participants (29 females) with a median age of 31
(range of 18–67). The study protocol was approved by the Newcastle
University, Faculty of Medical Sciences Ethical Review Process and
registered with ClinicalTrials.gov (NCT03477981). All participants
were within the Newcastle area, over 18 years old, free from any known
chronic illnesses and were not planning any changes in dietary habits,
physical activity or in body weight for six months prior to and during
the study. Participants were instructed to replace bread they normally
consumed with the breads provided by the study team. This study
lasted 4 weeks in total and participants were given control bread for the
first two weeks (week 1 and week 2), followed by the alginate bread for
a further two weeks (week 3 and week 4). All bread was provided upon
request by the study team. Participants filled in daily food diaries and
completed a visual analogue scale (VAS) wellbeing questionnaire after
their main evening meal. The validity, reproducibility and use of VAS
has previously been reported (Flint, Raben, Blundell, & Astrup, 2000)
and was therefore selected to subjectively assess gastrointestinal well-
being after consuming alginate and control bread. The VAS used a
100mm line, which expressed the most positive feelings at one end and
the most negative feelings at the other end. A second series of VAS
questions were answered at the end of every week. Both questionnaires
(asking both sets of questions) were completed 24 h prior to study
commencement to provide baseline data. Dietary intake was assessed
across both treatments using 7 day unweighted food diaries completed
each week of the intervention, with portion size estimates coming from
nationally (UK) representative data (Agency, 2014). These data were
subsequently processed by an independent researcher blinded to the
study design for energy macronutrient and dietary fiber intakes, with
outputs from the dietary analysis software NetWISP (version 3.0 for
Windows, Tinuviel Software, Warrington, UK). All 54 participants
completed both treatment arms across the four weeks for the bread
acceptability study.
2.2.2. Fat digestion study
The fat digestion study was a double-blind, randomised, controlled
cross-over pilot study (with all randomisation by an independent re-
searcher) which assessed the acute physiological impact of a single
high-fat test meal containing alginate. The study protocol was approved
by the County Durham & Tees Valley Research Ethics Committee, UK
(10/H0908/44) and all participants gave written informed consent. The
study was registered with ClinicalTrials.gov (NCT03350958).
Participants were recruited from areas around Newcastle Upon
Tyne, UK, through advertising and attending gastroenterology and
ileostomy meetings. Inclusion criteria were: non-smoking, 18 years and
over, have a well-functioning and stable ileostomy for at least 2 years,
have not been pregnant in the past twelve months or planning to be,
and not planning to change dietary habits or levels of physical activity
during the study. Twenty nine volunteers completed the study (17 fe-
males), BMI of 27.4 (± 0.02) with a median age of 61 (range 32–83)
with 28 volunteers giving blood samples.
Participants underwent telephone screening before being invited to
attend the research facility for an induction visit. Participants were
provided with two identical meals and two 500mL bottles of water to
take home with them. Participants were instructed to consume one
meal and one bottle of water on the evening prior to their two visits to
the study centre (plus any additional water ad libitum). Participants
were randomly allocated to one of two treatment groups, Group A or
Group B by an independent researcher. Group A received 100 g of al-
ginate bread, as toast, with 20 g of butter, whereas Group B received
100 g of control bread, as toast, with 20 g of butter. The treatments
were reversed for the second visit. Participants were instructed to fast
for at least 12 h prior to arriving at the study centre for each visit. Upon
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arrival, ileal effluent and fasting blood samples were collected and
wellbeing questionnaires were filled out, participants were then pro-
vided with their test meal and water. Blood samples, effluent samples
and wellbeing questionnaires were collected every 30min following
consumption of the test meal. Effluent was weighed and stored at
−20 °C along with plasma samples until further analysis. Participants
returned to the study centre two to four weeks later and the second
acute meal study was performed. Total lipid extraction of ileal effluent
was performed as previously described (Folch, Lees, & Sloane Stanley,
1957) and total plasma triglycerides were measured. Seven participants
originally recruited did not complete the fat digestion study due to
personal time constraints, not because of any aspects of the experi-
mental protocol. Thus data are presented for twenty-nine participants
who completed the fat digestion study. Of these only 26 volunteers
produced sufficient ileal effluent for measurements and only 28 vo-
lunteers provided blood samples.
2.3. Statistical analysis
Data from the acceptability study VAS were analysed by one way
ANOVA with Kruskal-Wallis multiple comparison test. Energy, dietary
fiber (as non-starch polysaccharide) and macronutrient data were
analysed by Wilcoxon matched pairs signed rank test. A paired t-test
was used to test total plasma triglycerides, effluent weights, and total
lipid content. Data are presented as the mean with standard error of the
mean (± S.E.M.) Statistical significance was set at p≤ 0.05. Statistical
analyses were performed using Graphpad Prism software (Version 6, La
Jolla, CA, USA).
4. Results
4.1. Bread acceptability study
In the daily wellbeing questionnaire, participants felt significantly
more alert when consuming alginate bread compared with control
bread (week 1) during weeks 3 and 4. Participants also felt calmer and
more relaxed, when consuming alginate bread (week 4 only) compared
with control bread (week 1 only) (Table 1). Participants were sig-
nificantly fuller when consuming the alginate bread compared with
baseline and week 1 but there were no differences in feelings of nausea,
bloatedness or flatulence during the four weeks on either treatment.
Weekly questions were also very similar between the alginate and
control bread over the duration of the study (Table 2). There was,
however, a significant difference between baseline and week 4 where
participants had an increase in ‘light-headedness or dizziness when
consuming alginate bread (P < 0.05) (Table 2). Similarly there was
also an increase at week 4 (alginate bread) of ‘blurred vision’ compared
with baseline. There was also a statistical increase in abdominal dis-
comfort, between baseline and weeks 2 (control bread), 3, and 4 (al-
ginate bread), however there were no differences between the weeks
when either bread was consumed. Abdominal pain or discomfort was
also significantly higher during the measurement period compared with
baseline. There was also a significant increase in flatulence between
baseline and week 3, the first week consuming alginate bread although
the differences were very small (a change of 0.6 on the VAS).
Total dietary intakes of energy, carbohydrate and protein were not
significantly different between the periods consuming control and al-
ginate breads (P > 0.05) (Table 3). Daily fat intake was significantly
higher during the alginate bread period although the median values
were very similar. The intake of non-starch polysaccharides (NSP) was
significantly increased by about 2 g/d as expected when the volunteers
were consuming alginate bread compared with the standard white
bread and the percentage of NSP from bread increased significantly
from 13 to 29%.
4.2. Fat digestion
The ileal effluent from the volunteers was weighed and grouped into
four time periods; 0–30, 31–120, 121–210 and 211–300min, and
combined to calculate total effluent weight for alginate and control
bread (Fig. 1). The weight of the effluent increased with consumption of
alginate bread in three out of the four time periods, with the largest
increase (291 g) occurring between 211 and 300min. Cumulatively, an
increase in weight of 478 g of ileal effluent was observed when the
participants consumed alginate bread.
The lipid content recovered in effluent fluid was similar for alginate
and control bread from 0 to 30 and 31–120min (Fig. 2). However, there
was a significant increase in lipid content in the effluent from 121 to
210 to 211–300min after consumption of alginate bread (3.8 g ± 1.6).
Overall there was an average increase of 1.1 g ± 0.5 of lipid content in
the ileal effluent when volunteers consumed alginate bread.
The initial measurements of triacylglycerol in plasma were within
expected normal fasting range (Fig. 3). Alginate bread consistently re-
duced plasma triacylglycerol, although the individual time points were
not significantly different when compared with the control bread. A 2%
reduction in area under the curve was seen for the concentration of
total triacylglycerol in plasma when volunteers consumed alginate
bread compared with control bread, although again this was not sig-
nificant.
5. Discussion
This is the first study to demonstrate that alginate enriched bread
was well tolerated and capable of attenuating lipid digestion. Alginate
enriched bread and control bread were equally well tolerated, with only
minor adverse side effects, with no withdrawals during the accept-
ability study. In the fat digestion study alginate enriched bread in-
creased effluent weight and lipid content in effluent (by an average of
1.1 g ± 0.5) and reduced total plasma triglycerides (by 2% AUC) in
ileostomy patients compared with control bread.
The addition of alginate to food or drink has been shown to reduce
subsequent food intake after a meal (Holt, Miller, Petocz, &
Table 1
Mean (± SD) visual analogue scale (VAS) of the wellbeing questions asked of volunteers at the end of every day.
0 – 10 Baseline Week 1 Week 2 Week 3 Week 4
Alert – Sleepy 3.3 ± 2.1a,b 3.8 ± 2.6a 3.4 ± 2.7a,b 3.1 ± 2.5b 3.0 ± 2.6b
Fine – Nauseous 1.1 ± 1.1a 2.0 ± 2.2a 1.8 ± 2.0a 2.0 ± 2.1a 1.8 ± 2.1a
Full – Starving 3.7 ± 1.8a 3.0 ± 2.1a,b 2.8 ± 2.0b,c 2.5 ± 1.9c 2.5 ± 2.0c
Not Bloated – Bloated 2.1 ± 2.0a 2.7 ± 2.7a 3.0 ± 2.8a 3.0 ± 2.6a 2.6 ± 2.5a
Not Flatulent – Flatulent 2.5 ± 2.6a 2.7 ± 2.5a 2.9 ± 2.5a 3.0 ± 2.6a 2.8 ± 2.6a
Calm – Irritable 2.2 ± 2.1a,b 2.6 ± 2.2a 2.4 ± 2.1a,b 2.3 ± 2.2a,b 2.1 ± 2.0b
Relaxed – Anxious 2.4 ± 2.1a,b 2.7 ± 2.2a 2.4 ± 2.1a,b 2.4 ± 2.2a,b 2.2 ± 2.0b
Baseline data was taken the day before the volunteers began the study. Week 1 and week 2 the volunteers only consumed the standard white bread, week 3 and week
4 volunteers only consumed alginate bread. Within each row, averages with the same letter are not statistically different based on analysis with a one way ANOVA
with Kruskal-Wallis multiple comparison test.
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Farmakalidis, 1995) but also reduces palatability (Georg Jensen,
Kristensen, Belza, Knudsen, & Astrup, 2012; Vuksan et al., 2009). The
reduction in palatability has been suggested to be due to the increase in
viscosity alginate gives and therefore, the alteration in mouthfeel
(Vuksan et al., 2009). However in this study we did not test the impact
of alginate on the orosensory modalities of bread. This increase in
viscosity is also likely to play a role in satiety and the reduced food
intake due to changes in the rate of stomach emptying (Holt et al.,
1995; Paxman, Richardson, Dettmar, & Corfe, 2008). In the present
study alginate was added to bread as a functional ingredient to po-
tentially reduce fat digestion, but a significant increase in the feeling of
fullness was also observed when consuming alginate bread (compared
with baseline data and the first week of control bread), confirming
previous studies that alginates increase satiety, decrease hunger and
reduce energy intake (Hoad et al., 2004; Jensen, Knudsen, Viereck,
Kristensen, & Astrup, 2012a; Paxman et al., 2008). Participants re-
ported an increase in alertness and reduced anxiety (in the daily
questionnaire) when consuming alginate bread compared with the first
week of the study. This may be due to potential apprehension of the
initiation of the trial, a new experience for many of the volunteers.
However, these data could be explained, in part, by a bias of the
subjects being able to differentiate between the breads.
In the weekly questionnaire there was an increase in abdominal
discomfort and abdominal pain for both the alginate and control bread,
although the difference was small. Previous studies using alginate food
products have not reported such findings (Georg Jensen, Kristensen, &
Astrup, 2011; Georg Jensen et al., 2012) and with the same increase
seen in the control bread, this may be due to the increase in con-
sumption of bread over their habitual levels. There was an increase in
the level of perceived flatulence during the first week consuming the
alginate bread. An increase in the consumption of NSP (1.8 g per day)
when consuming alginate bread may be a possible explanation for the
Table 2
Mean (± SD) visual analogue scale (VAS) of the wellbeing questions asked of volunteers at the end of week.
0 – 10 Baseline Week 1 Week 2 Week 3 Week 4
Light-headedness or dizziness?
Not at all – Very
0.7 ± 1.4a 1.2 ± 2.1a,b 0.9 ± 1.2a,b 1.4 ± 1.9a,b 1.3 ± 1.4b
Blurred Vision?
Not at all – Very
0.4 ± 0.6a 0.5 ± 1.0a,b 0.6 ± 0.8a,b 0.8 ± 2.1a,b 1.0 ± 1.3b
A difficulty to concentrate?
Not at all – Very
1.3 ± 1.7a 1.5 ± 1.7a 1.6 ± 1.8a 1.5 ± 1.8a 1.8 ± 2.0a
A difficulty to think?
Not at all – Very
1.2 ± 1.5a 1.4 ± 1.6a 1.5 ± 1.6a 1.6 ± 1.9a 1.5 ± 1.6a
Excessive thirst?
Not at all – Very
1.3 ± 1.8a 1.4 ± 1.7a 1.4 ± 1.4a 1.6 ± 1.6a 1.9 ± 2.0a
Headaches/migraines?
Not at all – Very
1.3 ± 2.0a 2.0 ± 2.5a 1.6 ± 2.1a 1.7 ± 2.1a 2.0 ± 2.4a
Craving for sweets?
Not at all – Very
2.4 ± 2.4a 2.2 ± 2.5a 2.6 ± 2.4a 2.1 ± 2.2a 2.5 ± 2.6a
Abdominal discomfort?
Not at all – Very
0.7 ± 0.9a 1.9 ± 2.4a,b 2.1 ± 2.3b 2.0 ± 2.2b 2.0 ± 2.3b
Bowel Habit?
Constipated – Diarrhoea
4.5 ± 0.8a 4.8 ± 1.3a 4.6 ± 1.2a 4.2 ± 1.3a 4.7 ± 1.4a
Urgency to pass stool?
Less than norm – More than norm
4.4 ± 0.9a 4.6 ± 1.3a 4.8 ± 1.0a 4.8 ± 1.0a 4.8 ± 1.3a
Abdominal pain or discomfort?
No pain – Terrible
1.7 ± 2.1a 2.6 ± 2.4a,b 3.0 ± 2.5b 2.7 ± 2.3a,b 3.2 ± 2.4b
Amount of flatulence?
Less than norm – More than norm
4.6 ± 1.2a 4.6 ± 1.6a,b 4.6 ± 1.6a,b 5.2 ± 1.3b 5.0 ± 1.7a,b
Baseline data was taken the day before the volunteers began the study. Week 1 and week 2 the volunteers only consumed the standard white bread, week 3 and week
4 volunteers only consumed alginate bread. Within each row averages with the same letter are not statistically different based on analysis with a one way ANOVA
with Kruskal-Wallis multiple comparison test.
Table 3
Dietary intake data across the two treatment groups.
Treatment Standard (median
(IQR))
Alginate (median
(IQR))
P-value
Energy intake (MJ/
d)
7.4 (6.5–8.9) 7.7 (5.8–8.8) 0.164
CHO intake (g/d) 198.7 (168.2–240.4) 200.2 (168.3–246.9) 0.707
Protein intake (g/
d)
75 (66.6–85.2) 74.7 (65.6–81.6) 0.527
Fat intake (g/d) 68.8 (55.1–79.9) 68.9 (49.9–80.6) 0.012
NSP intake (g/d) 11 (8.2–13.0) 12.8 (10.7–15.8) < 0.001
Slices of bread (/d) 1.8 (1.4–2.3) 1.8 (1.4–2.2) 0.543
% NSP from bread 12.9 (9.9–17.5) 28.5 (23.9–35.8) < 0.001
All values represent medians (Inter Quartile Range), CHO – carbohydrate, NSP
– Non-starch polysaccharide.
Fig. 1. wt of ileal effluent following consumption of alginate bread and control
bread. The weight of effluents were combined into four time periods; up to
30min, 31–120min, 121–210min and 211–300min, as well as a total weight
for each treatment. There are no error bars as the ileal effluent for all volunteers
was combined.
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increase in flatulence as more will enter the colon and be processed by
the microflora present. Continued ingestion of NSP increases the
availability of macronutrient, energy, and carbon sources to the mi-
crobial community and would be expected to alter the microflora over
time (Brownlee et al., 2005; Scott, Gratz, Sheridan, Flint, & Duncan,
2013) potentially reducing the level of flatulence. This increase in NSP
intake observed with alginate bread would also be beneficial in helping
people achieve the recommended intake of fiber (Howarth, Saltzman, &
Roberts, 2001), improve GI motility and maintain a healthy GI system
(Holt et al., 1995).
Increased fiber intake has been linked with modulating appetite, as
demonstrated in the current study with an increase in the feeling of
fullness (Kristensen & Jensen, 2011). Previous studies have reported
reduced daily energy consumption by 7% (Paxman et al., 2008) which
may be associated with weight loss in previous studies (Georg Jensen
et al., 2012). However in the current study there was no significant
difference in total energy intake between the control and alginate bread
consumption periods. The delivery vehicle will play a large role on the
effect of satiety with both of the aforementioned studies (Jensen et al.,
2012b; Paxman et al., 2008) using a drink to deliver the alginate. When
added to a drink alginate forms a viscous solution or gel in the stomach,
increasing the volume and activating stretch receptors. This increased
bolus in the stomach may therefore account for increased feeling of
fullness and reduced energy intake. Alginate cooked into bread is un-
likely to have the same effect and our in vitro data suggest that the
alginate may not actually be released from the bread matrix until it
reaches the duodenum (Houghton et al., 2014). Houghton et al. (2014)
showed a small release of alginate in the gastric phase from the bread
giving a concentration of around 0.1 mg/ml, below a gelling con-
centration (Houghton et al., 2014). In addition Houghton et al. (2015)
has shown that baking produces alginate fragments which would also
reduce its gelling potential (Houghton et al., 2015).
Unsurprisingly, NSP intake appeared to increase when participants
consumed the alginate bread compared with the standard bread by
approximately 3 g per day (see Table 1). It must be noted that overall
fiber intake was low within the participants and this increase in intake
still meant that only 1 out of 54 participants met their recommended
dietary allowance of NSP intakes of 24 g per day or above (England,
2015). This increase would equate to a relatively modest consumption
of the study bread, which provided approximately an extra 2 g of fiber
per slice compared with the control bread. Intake of bread ranged from
as low 0.6 slices a day to almost eight slices a day among the partici-
pants, although the intake between the two treatment groups was not
statistically different.
Alginate has previously been shown to inhibit pancreatic lipase
activity (Houghton et al., 2015; Wilcox et al., 2014). Any reduction in
activity would ultimately result in a reduction in fat digestion and ab-
sorption. In the current study, there was a 24% increase in effluent
weight and 40% increase of fat content in effluent fluid when partici-
pants consumed alginate bread. It is possible that some of the fat in the
ileal effluent for the alginate enriched bread arm of the study may have
in some part come from the extra fat in the bread. This may result, as it
may not be easily digested, due to colloidal changes occurring e.g the
alginate forming an acid gel trapping the fat. This can be ruled out
based on the work of Houghton et al. (2014) showing the alginate is
retained in the bread matrix and is not released until the higher pH of
the small intestine (Houghton et al., 2014). Ileostomists have been used
to demonstrate changes in ileal effluent lipid content before with con-
sumption of other fibers (Bosaeus, Carlsson, Sandberg, & Andersson,
1986; Higham & Read, 1992) but also with alginate (Sandberg et al.,
1994b). The small, six volunteer, study with alginate used milkshakes
as the vehicle but only measured free fatty acids – the breakdown
product of lipase activity (Sandberg et al., 1994b). However, they did
show an increase in the amount of free fatty acids leaving the small
intestine, potentially showing a higher level of lipase activity, contrary
to that proposed in this study. Alginate may also reduce transit time by
adding to the luminal bulk (Brownlee et al., 2010), which has been
linked with the water binding capacity of fiber (Chaplin, 2003;
Sandberg et al., 1994a). This may, in part, explain the increased ef-
fluent weight when participants consumed alginate bread. Alginate,
which should pass through the upper GI relatively undigested, may
contribute to the increased effluent weight reported here. A dry matter
measurement would have addressed this point but unfortunately was
not performed. Participants consumed alginate bread which included
4 g of alginate each, totalling 104 g (4×26) but this does not account
for the difference in total effluent weight (478 g) between the two arms.
These data suggest that alginate bread is able to increase effluent
weight possibly through water retention and increase fat recovered in
Fig. 2. The change in weight of lipid from consumption of control bread to
alginate bread. The weight of lipid in the effluent after consuming control bread
was subtracted from that of consuming alginate bread for each volunteer. The
figure shows the mean and standard error of each time point (up to 30, 31–120,
121–210, and 211–300min) as well as the average change in lipid content over
the total time period tested. * Indicate values significantly different to values at
31-120 min.
Fig. 3. Triacyl, diacyl and monoacylglycerol in plasma samples of volunteers
during consumption of the test meal and for 5 h after. Square symbols represent
data for control bread and solid circles represent data for alginate bread.
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effluent, potentially by inhibiting pancreatic lipase. This suggests that
alginate-enriched bread has potential as an obesity treatment and
should be explored further.
Any inhibition or delay of macronutrient digestion in the upper GI
tract will ultimately be reflected in the circulatory system. Previous
studies have observed reduction in blood glucose and insulin con-
centrations following the addition of alginate to a drink (Torsdottir,
Alpsten, Holm, Sandberg, & Tolli, 1991) and a cereal bar (Williams
et al., 2004). In the current study, the primary aim was to investigate
whether alginate added to bread was able to reduce fat digestion and
potentially plasma triglycerides. The reduction in plasma triacylgly-
cerol supports the additional effluent weight and the increase in total
lipid recovered in effluent. The potential mechanism for this is the re-
duced enzymatic activity of lipase in the small intestine that limits the
amount and rate of release of fatty acids, monoglycerides and glycerol
from the TAG in a meal, consequently reducing the rate of TAG re-
synthesis in the enterocytes. The fat content of the two breads were not
identical, alginate bread contained 13.3 g/100 g compared with 1.7 g/
100 g for the control. Despite more fat in the alginate bread the plasma
triglyceride concentrations appeared to be lower when participants
consumed alginate bread, suggesting that alginate may have attenuated
fat absorption. The level of pancreatic lipase released into the GI tract
would be far in excess of what would be needed to digest the fat present
in the meal given; therefore even if more fat was consumed, normal
pancreatic activity should be able to digest all the fat.
6. Conclusion
Incorporation of specific alginates in bread appears to limit the
amount of fat that can be absorbed from a single meal. Further long-
term studies are required to see if these findings translate to a positive
impact on body weight or cardiovascular health.
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